TACSTD2 and neoplasm: Among the solid tumor receptors that are targeted by these ADCs, HER2 is predominant, followed by EGFR, Trop2, MUC-1, Nectin4, CEACAM5, MSLN, 5T4, AXL, etc. For haematological malignancies, the primary targets are CD19, CD22, CD30, CD33, CD70 and KIT.